The total pancreatic cancer market size is expected to increase in the 7MM during the forecast period, driven by ongoing ...

Scientists developed an antibody treatment that reawakens the immune system to attack pancreatic tumors by blocking sugar-coated disguises cancer cells use to evade detection([1]) . Researchers also ...

Oncolytics Biotech Inc. (NASDAQ: ONCY) has secured FDA alignment on its pivotal Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning the company to launch the ...

Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical ...

Revolution Medicines has recently advanced daraxonrasib, its oral multi-selective RAS(ON) inhibitor, into a Phase III trial for metastatic pancreatic ductal adenocarcinoma and, in June 2025, received ...

Everyday habits such as heavy drinking and unhealthy eating can gradually damage the pancreas. Once injured, the consequences ...

Addressing why only some people develop cancer despite accumulating mutations, Dr Kalluri said, “Cancer is fundamentally a ...

Pancreatic cancer is one of the most aggressive cancers and has one of the lowest survival rates—only 10% after five years. One of the factors contributing to its aggressiveness is its tumor ...

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

The University of Hyderabad (UoH) on Wednesday hosted a distinguished lecture by Prof Raghu Kalluri, Chairman of Cancer Biology at the University of Texas MD Anderson Cancer Centre, under its ...

Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized ...

The NCI grant is allowing Xu’s team to continue dissecting the interactions among Lfng, Notch3, and other key signaling pathways involved in PDAC initiation and progression. The goal is to translate ...